Breaks Categories: News

MondayJun 26, 2017 9:48 am

NetworkNewsBreaks – ABcann Global Corporation (TSXV: ABCN) Extends University of Guelph Research Agreement through 2018

ABcann Global Corporation (TSXV: ABCN) this morning announced that it has amended and extended the research contract currently in place between its Canadian operating subsidiary, ABcann Medicinals Inc., and the University of Guelph in Ontario, Canada. The agreement, which is focused on controlled environment production of medicinal cannabis, now extends to December 31, 2018, and offers an option to extend further if mutually agreed upon. “ABcann has pursued a unique approach to controlled environment production of cannabis designed to standardize the production and quality of medical compounds,” Dr. Michael Dixon, director of the Controlled Environment Systems Research Facility at the…

Continue Reading

FridayJun 23, 2017 1:15 pm

NetworkNewsBreaks – BioDelivery Sciences (NASDAQ: BDSI) Receives Health Canada Approval of BELBUCA®; Plans to Launch In Early 2018

BioDelivery Sciences (NASDAQ: BDSI) this morning said that Health Canada has issued a Notice of Compliance (NOC) approving BELBUCA® for the management of opioid responsive pain severe enough to require daily, continuous, long-term treatment for which alternative options are inadequate. Approval is an important milestone for the company as it intends to commercialize BELBUCA in Canada through a partner. The launch of BELBUCA in Canada is expected in early 2018. "We believe BELBUCA offers important and distinctive advantages for those dealing with chronic pain, and we look forward to engaging with a commercial partner in Canada and for availability of…

Continue Reading

FridayJun 23, 2017 1:13 pm

NetworkNewsBreaks – ParkerVision, Inc. (NASDAQ: PRKR) Shares Plunge on Holding Decision in Infringement Case Against Apple (NASDAQ: AAPL)

Shares of ParkerVision (NASDAQ: PRKR) plunged 14% mid-day on news that the Regional Court of Munich is holding its decision in the ParkerVision v. Apple (NASDAQ: AAPL) infringement case until after the German Federal Patent Court rules on the associated pending nullity action. Similarly, the company’s final resolution in its German case against LG is pending the same action. The company expects a preliminary nullity decision before the end of 2017. “We remain optimistic that the Federal Patent Court will come to that conclusion yet this year enabling us to request the Regional Court to issue an enforceable injunction against…

Continue Reading

FridayJun 23, 2017 11:44 am

NetworkNewsBreaks – AVEO Oncology (NASDAQ: AVEO) Shares Skyrocket on CHMP’s Recommendation to Approve Tivozanib

AVEO Oncology (NASDAQ: AVEO) shares soared over 80% this morning on news that FOTIVDA™ has been recommended for approval as a treatment for patients with advanced renal cell carcinoma (RCC) by the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency. The CHMP's recommendation is referred to the European Commission, which is anticipated to make its final decision in approximately 67 days. Approval of FOTIVDA™ would also result in R&D reimbursement and milestone payments for the company. “If the European Commission grants marketing approval for tivozanib, it would trigger a $4 million research…

Continue Reading

ThursdayJun 22, 2017 1:38 pm

NetworkNewsBreaks – DelMar Pharmaceuticals (NASDAQ: DMPI) Shares Rise on IRB Approval for VAL-083 STAR-3 GBM Trial

DelMar Pharmaceuticals (NASDAQ: DMPI) shares are moving 21% higher today on news that the company has Institutional Review Board (IRB) approval to conduct its pivotal phase 3 study in Temozolomide-Avastin (bevacizumab) Recurrent GBM (STAR-3). IRBs are required under FDA regulations to review all human subject research to guarantee that the rights and welfare of human subjects are protected at all times. The VAL-083 STAR-3 GBM trial and all relevant study related materials were critically examined by the leading independent institutional review board and approved without any modifications. "We are pleased to remain on track to open enrollment in this trial…

Continue Reading

ThursdayJun 22, 2017 12:53 pm

NetworkNewsBreaks – Integral Technologies, Inc.’s (ITKG) ElectriPlast Conductive Plastic Chosen For Long-Term Deal By European Electric Car Maker

Integral Technologies (OTC: ITKG), together with its wholly owned subsidiary ElectriPlast Corp., reports that its ElectriPlast material has been selected by a leading European electric luxury SUV manufacturer for use in a high voltage connector. The order marks the company’s second ElectriPlast order so far this year and the first European automotive commercial order. The electric SUV is expected to make its European debut in late 2017, and the order will run through 2024. "We never waivered in our belief that there was tremendous potential in the automotive industry for conductive plastic and this is just another validation. Now that…

Continue Reading

ThursdayJun 22, 2017 9:50 am

NetworkNewsBreaks – ORHub, Inc. (ORHB) Platform Featured in ‘Customer Stories’ Piece by Microsoft

Health care software-as-a-service company ORHub, Inc. (OTC: ORHB) was recently highlighted as part of a customer story created by tech giant Microsoft (NASDAQ: MSFT) covering the Hoag Orthopedic Institute (HOI). The informative piece gives readers some insight into HOI’s efforts to advance orthopedic care, particularly as they relate to ORHub, an innovative surgical resource management solution running on the Microsoft Azure platform and accessible in the operating room using a Microsoft Surface device. “With ORHub, HOI is improving teamwork, automating manual processes, and better understanding resource allocation in its spinal surgeries,” the article reads. Richard Lee, MD, an orthopedic surgeon…

Continue Reading

WednesdayJun 21, 2017 3:03 pm

NetworkNewsBreaks – Moleculin Biotech, Inc. (NASDAQ: MBRX) Reports Discovery of Metabolic Inhibitor with Potential to Treat Pancreatic Cancer; Shares Rise

Shares of Moleculin Biotech (NASDAQ: MBRX) are up more than 30% after the company said that WP1234, a metabolic inhibitor, is a positive drug candidate to be studied for the potential to treat pancreatic cancer. Pancreatic cancer is still considered mostly untreatable, so any improvement in treating this disease could symbolize a significant clinical benefit. "We have identified possible new properties of our compound WP1234, a modification to WP1122. In pre-clinical testing, WP1234 has shown improved drug characteristics when compared with WP1122 and a 20 to 50-fold greater ability to kill pancreatic cancer cell lines when compared with traditional inhibitors…

Continue Reading

WednesdayJun 21, 2017 3:00 pm

NetworkNewsBreaks – Grow Condos, Inc. (GRWC) Provides Positive Update on ‘Smoke on the Water’ at Lake Selmac

Grow Condos (OTCQB: GRWC) this morning provided an update on "Smoke on the Water" at Lake Selmac, the company’s resort designed to cater to and capitalize on the country's persistently increasing level of recreational marijuana acceptance. The company reports that the park is undergoing a series of alterations, including culturally diverse upgrades and added value services for patrons of the resort. Among the highlights of the park’s changing atmosphere are the delivery of its tee-pees for its Native American section, which also features yoga and other spiritually enhancing activities. "Smoke on the Water" has launched its own roll up development…

Continue Reading

WednesdayJun 21, 2017 11:29 am

NetworkNewsBreaks – ORHub, Inc. (ORHB) Announces Exercise Price for Series B and D Warrants

Health care software-as-a-service company ORHub, Inc. (OTC: ORHB) today announced a $0.50 exercise price for all of its Series B and D warrants. Per this morning’s news release, the exercise price will commence immediately and remain in place until all of the related warrants have been exercised or have reached their expiration date, currently set at December 31, 2017. If all of the Series B and D warrants are exercised, the company estimates that it will receive more than $5.5 million in additional proceeds with which to fund the launch of its innovative software platform into hospital chains located throughout…

Continue Reading